Joint Formulary & PAD

Oxazepam - Anxiety

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Associated Icons :
SPC
Restrictions / Comments :

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Oxazepam
Indication :
Anxiety
Group Name :
Keywords :
Brand Names Include :
Important Information :

Initiation in Primary Care on request from the Mental Health specialist team.

Consider use where clinically relevant liver impairment - oxazepam is less significantly metabolised by the liver than other benzodiazepines.

Do not offer a benzodiazepine for the treatment of anxiety disorder in primary or secondary care except as a short-term measure (2-4 weeks) during crisis. Follow the advice in the BNF.

Avoid in the elderly.

Beware of MHRA advice on coprescribing of benzodiazepines and opioid and risk of death.

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Committee Recommendations (0)

  • No records returned.

Other Indications

Below are listed other indications that Oxazepam is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Anxiety.